(Total Views: 52)
Posted On: 10/14/2025 10:00:22 AM
Post# of 99594
$KRTL Biotech Advances Global Access to Women’s Health Pharmaceuticals Through Strategic Portfolio Expansion
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=495814
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company"
today announced that its subsidiary, KRTL Biotech, Inc., is spotlighting its expanding women’s health pharmaceutical portfolio, which includes critical treatments supporting reproductive wellness, maternal care, and gynecological health.
The products, developed in collaboration with Industria Químico-Farmacéutica SIGMA Corp., represent one of the most socially impactful categories within the Company’s international pipeline. These therapeutics are widely used across Latin America in both clinical and over-the-counter settings and are now under evaluation for global export and U.S. regulatory pathways.
"Women’s health is foundational to community health," said Daniel Bishop, CEO of KRTL Biotech. "Our product line addresses real needs — from prenatal support to gynecological infections — using formats that meet international standards for safety, accessibility, and affordability."
Featured Women’s Health Products:
The portfolio includes prenatal supplements such as iron with folic acid and multivitamins, as well as gynecological treatments like clotrimazole (in both topical and vaginal formulations) and fluconazole. It also encompasses vaginal antiseptics, probiotics, and therapeutic products designed to support menstrual care and hormonal balance.
These formulations are actively distributed across Bolivia through public health channels, pharmacies, and hospital procurement. Several of these products are listed on national formularies and are already included in maternal and child health programs.
Together, these products empower caregivers, clinics, and women with options for preventive care, treatment of infections, and nutritional support during pregnancy.
"At SIGMA, we have long understood that advancing women’s health is not only a clinical goal but a social imperative," said Patricia Wilstermann, CEO of SIGMA. "We’re proud that these products serve both the public and private sectors in Bolivia — and we’re even more proud to bring this experience to a global platform with KRTL."
KRTL Biotech is currently exploring regulatory alignment for select women’s health products in the U.S. and other regions. Several supplements and topicals are eligible for classification under OTC Monograph frameworks, while prescription antifungals and prenatal complexes may qualify for ANDA submission or international export approvals.
"As we expand our women’s health footprint, we’re doing so with a clear commitment to equity, quality, and responsible commercialization," said Cesar Herrera, CEO of KRTL Holding Group Inc. "These products speak directly to unmet health needs worldwide — and we’re prepared to deliver."
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=495814
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company"
today announced that its subsidiary, KRTL Biotech, Inc., is spotlighting its expanding women’s health pharmaceutical portfolio, which includes critical treatments supporting reproductive wellness, maternal care, and gynecological health. The products, developed in collaboration with Industria Químico-Farmacéutica SIGMA Corp., represent one of the most socially impactful categories within the Company’s international pipeline. These therapeutics are widely used across Latin America in both clinical and over-the-counter settings and are now under evaluation for global export and U.S. regulatory pathways.
"Women’s health is foundational to community health," said Daniel Bishop, CEO of KRTL Biotech. "Our product line addresses real needs — from prenatal support to gynecological infections — using formats that meet international standards for safety, accessibility, and affordability."
Featured Women’s Health Products:
The portfolio includes prenatal supplements such as iron with folic acid and multivitamins, as well as gynecological treatments like clotrimazole (in both topical and vaginal formulations) and fluconazole. It also encompasses vaginal antiseptics, probiotics, and therapeutic products designed to support menstrual care and hormonal balance.
These formulations are actively distributed across Bolivia through public health channels, pharmacies, and hospital procurement. Several of these products are listed on national formularies and are already included in maternal and child health programs.
Together, these products empower caregivers, clinics, and women with options for preventive care, treatment of infections, and nutritional support during pregnancy.
"At SIGMA, we have long understood that advancing women’s health is not only a clinical goal but a social imperative," said Patricia Wilstermann, CEO of SIGMA. "We’re proud that these products serve both the public and private sectors in Bolivia — and we’re even more proud to bring this experience to a global platform with KRTL."
KRTL Biotech is currently exploring regulatory alignment for select women’s health products in the U.S. and other regions. Several supplements and topicals are eligible for classification under OTC Monograph frameworks, while prescription antifungals and prenatal complexes may qualify for ANDA submission or international export approvals.
"As we expand our women’s health footprint, we’re doing so with a clear commitment to equity, quality, and responsible commercialization," said Cesar Herrera, CEO of KRTL Holding Group Inc. "These products speak directly to unmet health needs worldwide — and we’re prepared to deliver."
(0)
(0)
